Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
- PMID: 17080912
- DOI: 10.1177/0961203306071872
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
Abstract
Antimalarials have shown beneficial effects on systemic lupus erythematosus (SLE) activity. Our aim was to investigate whether antimalarials protect against thrombosis and influence survival in SLE patients. A prospective cohort including 232 patients with SLE were included in the study at the time of lupus diagnosis. End points were documented thrombosis and death due to any cause. A Cox regression-multiple-failure time survival analysis model was fitted to establish the effect of antimalarials on the development of thrombosis. Kaplan-Meier survival curves and propensity score adjusted-Cox regression analysis were performed to investigate the effect of antimalarials use on survival. Of our subjects, 204 patients (88%) were women. 230 patients (99%) were white. 150 patients (64%) had ever received antimalarials. Median time on antimalarials was 52 months (range three to 228 months). The Cox multiple-failure time survival analysis showed that taking antimalarials was protective against thrombosis (HR 0.28, 95% CI 0.08-0.90), while aPL-positivity (HR 3.16, 95% CI 1.45-6.88) and previous thrombosis (HR 3.85, 95% CI 1.50-9.91) increased the risk of thrombotic events. Twenty-three patients died, 19 of whom (83%) had never received antimalarials. No patient treated with antimalarials died of cardiovascular complications. Cumulative 15-year survival rates were 0.68 for never versus 0.95 for ever treated patients (P < 0.001). Age at diagnosis and propensity score-adjusted HR for antimalarials ever versus never users was 0.14 (95% CI 0.04-0.48). Our study shows a protective effect of antimalarials against thrombosis and an increased survival of SLE patients taking these drugs. These data support the routine use of antimalarials in all patients with SLE.
Similar articles
-
Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.Arthritis Rheum. 2010 Mar;62(3):855-62. doi: 10.1002/art.27300. Arthritis Rheum. 2010. PMID: 20131238
-
Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark.Lupus. 2015 Mar;24(3):299-306. doi: 10.1177/0961203314555351. Epub 2014 Oct 15. Lupus. 2015. PMID: 25318969
-
Antimalarials may influence the risk of malignancy in systemic lupus erythematosus.Ann Rheum Dis. 2007 Jun;66(6):815-7. doi: 10.1136/ard.2006.067777. Epub 2007 Jan 4. Ann Rheum Dis. 2007. PMID: 17204564 Free PMC article.
-
Thrombosis in systemic lupus erythematosus: risk and protection.Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1541-9. doi: 10.1586/erc.09.137. Expert Rev Cardiovasc Ther. 2009. PMID: 19954316 Review.
-
The incidence and prevalence of systemic lupus erythematosus in Thrace, 2003-2014: A 12-year epidemiological study.Lupus. 2016 Jan;25(1):102-9. doi: 10.1177/0961203315603141. Epub 2015 Sep 7. Lupus. 2016. PMID: 26345673 Review.
Cited by
-
Inhibitory effect of hydroxychloroquine on glucocorticoid-induced osteoporosis in lupus therapy.Clin Transl Immunology. 2024 Oct 14;13(10):e70010. doi: 10.1002/cti2.70010. eCollection 2024. Clin Transl Immunology. 2024. PMID: 39416769 Free PMC article.
-
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.Lupus. 2012 Jul;21(8):830-5. doi: 10.1177/0961203312437270. Epub 2012 Feb 17. Lupus. 2012. PMID: 22343096 Free PMC article.
-
Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE.Lupus Sci Med. 2019 Jun 27;6(1):e000321. doi: 10.1136/lupus-2019-000321. eCollection 2019. Lupus Sci Med. 2019. PMID: 31321062 Free PMC article.
-
Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview.Adv Ther. 2018 Apr;35(4):439-456. doi: 10.1007/s12325-018-0686-0. Epub 2018 Mar 20. Adv Ther. 2018. PMID: 29556907 Free PMC article. Review.
-
Management of cardiovascular disease in patients with systemic lupus erythematosus.Expert Opin Pharmacother. 2020 Sep;21(13):1617-1628. doi: 10.1080/14656566.2020.1770227. Epub 2020 Jun 8. Expert Opin Pharmacother. 2020. PMID: 32511034 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical